MedTrace Logo

VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer

NCT05374538 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2025-05-01

Study results available
· View outcomes & findings →

Summary

This is a Phase 1a/1b study of aurora kinase A inhibitor VIC-1911 administered as monotherapy and in combination with sotorasib for the treatment of locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer(NSCLC).

Conditions

Interventions

DRUG

VIC-1911

VIC-1911 tablets for oral administration

DRUG

sotorasib

Sotorasib tablets for oral administration

Sponsors & Collaborators

  • Westat

    collaborator OTHER

  • Vitrac Therapeutics, LLC

    lead INDUSTRY

Principal Investigators

  • Sarah Goldberg, MD, MPH · Yale Cancer Center, Yale University

  • Linda J Paradiso, DVM · Vitrac Therapeutics, LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-09
Primary Completion
2023-08-26
Completion
2023-08-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05374538 on ClinicalTrials.gov